Equities researchers at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the medical technology company’s stock.
A number of other equities analysts also recently commented on the stock. Benchmark reaffirmed a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets decreased their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.
Check Out Our Latest Stock Analysis on BIOLASE
BIOLASE Stock Performance
BIOLASE (NASDAQ:BIOL – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical technology company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $11.56 million during the quarter. BIOLASE had a negative return on equity of 1,782.73% and a negative net margin of 41.65%.
Hedge Funds Weigh In On BIOLASE
A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC grew its position in shares of BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 143,537 shares of the medical technology company’s stock after acquiring an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 as of its most recent filing with the SEC. 8.79% of the stock is owned by institutional investors and hedge funds.
About BIOLASE
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Further Reading
- Five stocks we like better than BIOLASE
- What Are the U.K. Market Holidays? How to Invest and Trade
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Business Services Stocks Investing
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Investing in Commodities: What Are They? How to Invest in Them
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.